Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys

Abstract Vaccines based on adenovirus (Ad) vectors are currently in development against several pathogens. However, neutralizing antibodies (NAb) to human adenovirus type 5 (AdHu5), the best-studied vector, are highly prevalent in humans worldwide. Less-prevalent adenoviruses, including human and si...

Full description

Saved in:
Bibliographic Details
Published in:Virology (New York, N.Y.) N.Y.), 2010-11, Vol.407 (1), p.1-6
Main Authors: Ersching, Jonatan, Hernandez, Malva I.M, Cezarotto, Fabrizzio S, Ferreira, Jovino D.S, Martins, Amely B, Switzer, William M, Xiang, Zhiquan, Ertl, Hildegund C.J, Zanetti, Carlos R, Pinto, Aguinaldo R
Format: Article
Language:English
Subjects:
Adenoviridae Infections - immunology
Adenoviridae Infections - veterinary
Adenovirus
Adenoviruses, Human - immunology
Adenoviruses, Simian - immunology
Adolescent
Adult
Aged
Animals
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Brazil
Female
Human adenovirus
Humans
Infectious Disease
Male
Middle Aged
Neutralizing antibody
Platyrrhini
Primate Diseases - immunology
Primate Diseases - virology
Seroepidemiologic Studies
Seroneutralization assay
Simian adenovirus
Vaccines
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Vaccines based on adenovirus (Ad) vectors are currently in development against several pathogens. However, neutralizing antibodies (NAb) to human adenovirus type 5 (AdHu5), the best-studied vector, are highly prevalent in humans worldwide. Less-prevalent adenoviruses, including human and simian serotypes, provide alternative vaccine platforms. In this study, sera from 200 Brazilian human subjects and New-World monkeys were tested for NAb titers to human serotypes AdHu5 and AdHu26 and chimpanzee-origin Ad viruses of serotype 6 (AdC6) and serotype 68 (AdC68). Seroprevalence rates of NAb in humans were 69.5% for AdHu5, 44% for AdHu26, 21% for AdC6 and 23.5% for AdC68. In addition, NAb titers to human Ad were consistently higher than those found to simian serotypes. Surprisingly, sera from some New-World monkey species were able to neutralize AdC6 and/or AdC68. A possible explanation for these findings and the implications for the development of Ad-vector vaccines are discussed in detail.
ISSN:0042-6822
1096-0341
DOI:10.1016/j.virol.2010.07.043